RU2017106794A - Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк - Google Patents

Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк Download PDF

Info

Publication number
RU2017106794A
RU2017106794A RU2017106794A RU2017106794A RU2017106794A RU 2017106794 A RU2017106794 A RU 2017106794A RU 2017106794 A RU2017106794 A RU 2017106794A RU 2017106794 A RU2017106794 A RU 2017106794A RU 2017106794 A RU2017106794 A RU 2017106794A
Authority
RU
Russia
Prior art keywords
bccc
modification
use according
paragraphs
amino acid
Prior art date
Application number
RU2017106794A
Other languages
English (en)
Russian (ru)
Other versions
RU2017106794A3 (enExample
Inventor
Карл ШВЕЙГХОФЕР
Карл ЭКЕРТ
Хсу-Пин Куо
Бетти Чан
Даррин БОПРЕ
Лео ЧЕУН
Original Assignee
Фармасайкликс Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармасайкликс Элэлси filed Critical Фармасайкликс Элэлси
Publication of RU2017106794A publication Critical patent/RU2017106794A/ru
Publication of RU2017106794A3 publication Critical patent/RU2017106794A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57557
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • G01N2333/4706Regulators; Modulating activity stimulating, promoting or activating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017106794A 2014-08-01 2015-07-31 Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк RU2017106794A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462032430P 2014-08-01 2014-08-01
US62/032,430 2014-08-01
US201562119668P 2015-02-23 2015-02-23
US62/119,668 2015-02-23
US201562127484P 2015-03-03 2015-03-03
US62/127,484 2015-03-03
PCT/US2015/043300 WO2016019341A1 (en) 2014-08-01 2015-07-31 Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor

Publications (2)

Publication Number Publication Date
RU2017106794A true RU2017106794A (ru) 2018-09-03
RU2017106794A3 RU2017106794A3 (enExample) 2019-02-27

Family

ID=55179406

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017106794A RU2017106794A (ru) 2014-08-01 2015-07-31 Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк

Country Status (13)

Country Link
US (1) US20160032404A1 (enExample)
EP (1) EP3185870A4 (enExample)
JP (1) JP2017523188A (enExample)
KR (1) KR20170042614A (enExample)
CN (1) CN106714804A (enExample)
AU (1) AU2015296010A1 (enExample)
BR (1) BR112017001677A2 (enExample)
CA (1) CA2955744A1 (enExample)
IL (1) IL250221A0 (enExample)
MX (1) MX2017001302A (enExample)
RU (1) RU2017106794A (enExample)
SG (1) SG11201700774UA (enExample)
WO (1) WO2016019341A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
ME03010B (me) 2008-10-22 2018-10-20 Array Biopharma Inc Jedinjenja supstituisanog pirazol0[1,5-]pirimidina као inhibitori trk kinaze
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL2918588T3 (pl) 2010-05-20 2017-10-31 Array Biopharma Inc Związki makrocykliczne jako inhibitory kinazy TRK
CA3113343C (en) 2010-06-03 2024-10-08 Pharmacyclics Llc USE OF BRUTON'S TYROSINE KINASE INHIBITORS IN THE TREATMENT OF FOLLICULAR LYMPHOMA
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
WO2016071770A2 (en) * 2014-11-05 2016-05-12 Janssen Pharmaceutica Nv Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same
TWI767858B (zh) 2014-11-16 2022-06-11 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
KR102632745B1 (ko) 2015-04-06 2024-02-01 얀센 파마슈티카 엔브이 이브루티닙을 함유하는 조성물
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
DK3439662T3 (da) 2016-04-04 2024-09-02 Loxo Oncology Inc Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3458456B1 (en) 2016-05-18 2020-11-25 Loxo Oncology Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11085039B2 (en) 2016-12-12 2021-08-10 xCella Biosciences, Inc. Methods and systems for screening using microcapillary arrays
JP7356351B2 (ja) * 2016-12-12 2023-10-04 エクセラ・バイオサイエンシーズ・インコーポレイテッド マイクロキャピラリーアレイを使用したスクリーニングのための方法およびシステム
CN110382439A (zh) 2016-12-30 2019-10-25 埃克切拉生物科学公司 多级样品回收系统
JOP20190213A1 (ar) * 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110996972A (zh) * 2017-06-08 2020-04-10 恩立夫克治疗有限责任公司 用于癌症治疗的治疗性凋亡细胞
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EA202190045A1 (ru) * 2018-06-15 2021-03-17 Янссен Фармацевтика Нв Составы/композиции, содержащие ибрутиниб
GB2577909B (en) * 2018-10-10 2020-11-18 Symetrica Ltd Gamma-ray spectrum classification
JP2022513666A (ja) * 2018-11-30 2022-02-09 ヤンセン バイオテツク,インコーポレーテツド 濾胞性リンパ腫の治療方法
EP3890876B1 (en) 2018-12-06 2024-05-01 Xcella Biosciences, Inc. Lateral loading of microcapillary arrays
WO2021087044A1 (en) * 2019-10-30 2021-05-06 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2022169731A1 (en) * 2021-02-03 2022-08-11 Curis Inc. Biomarkers for fimepinostat therapy
US20230010803A1 (en) * 2021-06-30 2023-01-12 Janssen Pharmaceutica Nv Treatments for diffuse large b-cell lymphoma
JP2024526241A (ja) * 2021-06-30 2024-07-17 ヤンセン ファーマシューティカ エヌ.ベー. ブルトン型チロシンキナーゼの阻害剤及びその使用方法
JP7423090B2 (ja) * 2022-04-07 2024-01-29 学校法人藤田学園 不明熱患者のb細胞リンパ腫診断補助キットおよび情報提供方法
WO2025080543A1 (en) * 2023-10-09 2025-04-17 Bristol-Myers Squibb Company Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
JP7696987B1 (ja) * 2023-12-22 2025-06-23 東洋鋼鈑株式会社 遺伝子変異を検出する方法
JP7698850B1 (ja) 2023-12-22 2025-06-26 東洋鋼鈑株式会社 遺伝子変異評価用キット

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113343C (en) * 2010-06-03 2024-10-08 Pharmacyclics Llc USE OF BRUTON'S TYROSINE KINASE INHIBITORS IN THE TREATMENT OF FOLLICULAR LYMPHOMA
US20130102477A1 (en) * 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
BR112014009276A8 (pt) * 2011-10-19 2017-06-20 Pharmacyclics Inc uso de inibidores de tirosina quinase de bruton (btk)
AR088570A1 (es) * 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
KR20150015021A (ko) * 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 브루톤 타이로신 키나아제 저해제의 결정 형태
US10954567B2 (en) * 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
WO2014110114A1 (en) * 2013-01-10 2014-07-17 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Also Published As

Publication number Publication date
SG11201700774UA (en) 2017-02-27
EP3185870A1 (en) 2017-07-05
CN106714804A (zh) 2017-05-24
AU2015296010A1 (en) 2017-02-02
KR20170042614A (ko) 2017-04-19
RU2017106794A3 (enExample) 2019-02-27
US20160032404A1 (en) 2016-02-04
WO2016019341A1 (en) 2016-02-04
JP2017523188A (ja) 2017-08-17
BR112017001677A2 (pt) 2018-07-17
EP3185870A4 (en) 2018-06-20
CA2955744A1 (en) 2016-02-04
IL250221A0 (en) 2017-03-30
MX2017001302A (es) 2017-10-11

Similar Documents

Publication Publication Date Title
RU2017106794A (ru) Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк
JP2017523188A5 (enExample)
GB2613715B (en) Binding proteins specific for RAS neoantigens and uses thereof
IL284223A (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
JO3745B1 (ar) ناهضات بروتينات رابطة لل icos
EP3891290A4 (en) ADENO-ASSOCIATED VIRUS (AAV) PRODUCING CELL LINE AND METHODS
EA201201036A1 (ru) Целевые геномные изменения
PH12015502039B1 (en) Anti-lag-3 binding proteins
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
WO2017027571A8 (en) Mechanism of resistance to bet bromodomain inhibitors
WO2016065349A3 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
DK3145634T3 (da) Prøveudtagnings- og analysekit, prøveholder og fremgangsmåde
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
DE112020000392A5 (de) Greifvorrichtung zum Greifen von Laborgefäßen
IL284187A (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
IL289749A (en) Assay apparatuses, methods and reagents
WO2016198833A3 (en) Methods for analysing a urine sample
PL3601581T3 (pl) Sposoby hodowli komórkowej z użyciem inhibitorów hdac lub białek rep
MY173804A (en) Stable polypeptides binding to human complement c5
EP3494232A4 (en) BIOMARKERS FOR PREDICTING PREMATURE DELIVERY IN A GRAVID FEMALE EXPOSED TO PROGESTOGENS
GB201008720D0 (en) RxLR-leader peptides and protein translocation
EP3974528A4 (en) OLIGONUCLEOTIDE, METHOD AND OMICS ANALYSIS KIT
SG11202109520UA (en) Disposition of reagents in assay device
EP3726225A4 (en) SUPPORT FOR PLACING ANALYSIS PLATES, AND ANALYSIS KIT
GB2592552B (en) Blood vessel sample kit

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190711